Antibacterial Efficacy of Phages against Pseudomonas aeruginosa Infections in Mice and Drosophila melanogaster (cid:1)

Phage therapy against Pseudomonas aeruginosa infections has received renewed attention owing to the increasing prevalence of antibiotic resistance in this bacterium. Here, we isolated and characterized two new potentially lytic bacteriophages (MPK1 and MPK6), which produced large and clear plaques on P. aeruginosa strain PAO1. Based on their morphology, MPK1 belongs to the Myoviridae , while MPK6 belongs to the Podoviridae . The group B polysaccharide of lipopolysaccharide was required for infection, suggesting that their host spectra are associated with the serotypes of P. aeruginosa strains. Intramuscular and intraperitoneal administration of MPK1 and, to a lesser extent, MPK6 significantly protected mice from mortality caused by PAO1-induced peritonitis-sepsis ( P < 0.01). Mice treated with either phage also had lower bacterial burdens in their livers, lungs, and spleens. The antibacterial efficacy of MPK1 and MPK6 was also evaluated based on Drosophila melanogaster systemic infection caused by P. aeruginosa , for which phages were administered by feeding. Both phages significantly delayed the PAO1-induced killing of D. melanogaster ( P < 0.001), although MPK1 persisted longer than MPK6 in uninfected D. melanogaster tissue samples. These results suggest that a mini-scale experiment using D. melanogaster infection is valid for evaluating the antibacterial efficacy of phage therapy against P. aeruginosa infections.

[1]  Shin-Young Park,et al.  Drosophila melanogaster-Based Screening for Multihost Virulence Factors of Pseudomonas aeruginosa PA14 and Identification of a Virulence-Attenuating Factor, HudA , 2008, Infection and Immunity.

[2]  D. Scholl,et al.  Antibacterial Efficacy of R-Type Pyocins towards Pseudomonas aeruginosa in a Murine Peritonitis Model , 2008, Antimicrobial Agents and Chemotherapy.

[3]  G. Lau,et al.  Genome sequence comparison and superinfection between two related Pseudomonas aeruginosa phages, D3112 and MP22. , 2007, Microbiology.

[4]  J. Fralick,et al.  Phage Therapy of Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model , 2007, Antimicrobial Agents and Chemotherapy.

[5]  F. Ausubel,et al.  Antifungal Chemical Compounds Identified Using a C. elegans Pathogenicity Assay , 2007, PLoS pathogens.

[6]  You-Hee Cho,et al.  R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains. , 2007, Journal of microbiology and biotechnology.

[7]  Tetsuya Matsumoto,et al.  Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice , 2006, Antimicrobial Agents and Chemotherapy.

[8]  Frederick M Ausubel,et al.  Identification of novel antimicrobials using a live-animal infection model , 2006, Proceedings of the National Academy of Sciences.

[9]  You-Hee Cho,et al.  KatA, the Major Catalase, Is Critical for Osmoprotection and Virulence in Pseudomonas aeruginosa PA14 , 2005, Infection and Immunity.

[10]  Toshikazu Tani,et al.  Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[11]  L. Steinstraesser,et al.  Host defense peptides in burns. , 2004, Burns : journal of the International Society for Burn Injuries.

[12]  U. Bläsi,et al.  Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage , 2004, Antimicrobial Agents and Chemotherapy.

[13]  E. Anggard,et al.  Therapeutic use of bacteriophages. , 2004, The Lancet. Infectious diseases.

[14]  R. Gibson,et al.  Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management , 2003, Current opinion in pulmonary medicine.

[15]  E. Mahenthiralingam,et al.  Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. , 2002, American journal of respiratory and critical care medicine.

[16]  L. Wilkinson Félix d'Herelle and the origins of molecular biology , 2001, Medical History.

[17]  H. Ackermann Frequency of morphological phage descriptions in the year 2000 , 2001, Archives of Virology.

[18]  N. Barekzi,et al.  Efficacy of Locally Delivered Polyclonal Immunoglobulin against Pseudomonas aeruginosa Peritonitis in a Murine Model , 1999, Antimicrobial Agents and Chemotherapy.

[19]  H. Ackermann Tailed Bacteriophages: The Order Caudovirales , 1998, Advances in Virus Research.

[20]  C. Goodwin,et al.  Burn Wound Infections: Current Status , 1998, World Journal of Surgery.

[21]  K. Iczkowski,et al.  Bacteriophages show promise as antimicrobial agents. , 1998, The Journal of infection.

[22]  M. Levison,et al.  Peritonitis: update on pathophysiology, clinical manifestations, and management. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Robert L. Erwin Host-defense peptides , 1996, Nature Biotechnology.

[24]  T. Hayashi,et al.  Identification of the lipopolysaccharide core region as the receptor site for a cytotoxin-converting phage, phi CTX, of Pseudomonas aeruginosa , 1994, Journal of bacteriology.

[25]  S. Santacroce,et al.  Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  M. Gauderer,et al.  Pseudomonas aeruginosa as a primary pathogen in children with bacterial peritonitis. , 1987, Journal of pediatric surgery.

[27]  M. Dabrowski,et al.  Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. , 1987, Archivum immunologiae et therapiae experimentalis.

[28]  H. O. Senekjian,et al.  Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis. , 1982, Archives of internal medicine.

[29]  K. Jarrell,et al.  Pseudomonas aeruginosa bacteriophage phi PLS27-lipopolysaccharide interactions , 1981, Journal of virology.

[30]  J. Bartlett,et al.  Experimental Intra-Abdominal Abscesses in Rats: Development of an Experimental Model , 1974, Infection and immunity.

[31]  D. E. Bradley The length of the filamentous Pseudomonas aeruginosa bacteriophage Pf. , 1973, The Journal of general virology.

[32]  D. E. Bradley A pilus-dependent Pseudomonas aeruginosa bacteriophage with a long noncontractile tail. , 1973, Virology.

[33]  D. E. Bradley,et al.  Ultrastructure of bacteriophage and bacteriocins , 1967, Bacteriological reviews.